Last updated: December 26, 2025
Executive Summary
Patent JP2019505549, titled "Methods for treating neurological and psychiatric disorders," filed by Eisai Co., Ltd. in 2019, features a broad claim set surrounding the use of specific compounds for treating disorders such as Alzheimer's disease, schizophrenia, and depression. This patent embodies a strategic extension of Eisai's neurological portfolio, aiming to secure exclusivity on innovative use claims involving novel compounds and methods, aligned with global trends in CNS therapeutics.
This report dissects the patent’s scope, claims, and impacts within the patent landscape. It explores how the claims shape the competitive environment, analyzes overlaps with existing patents, and assesses potential implications for stakeholders. The focus is on delineating the breadth of protection, identifying key areas of innovation, and understanding the landscape dynamics.
1. Patent Summary and Background
- Application Filing Date: October 31, 2019
- Publication Date: November 21, 2019 (Japanese Patent Office publishing)
- Applicant: Eisai Co., Ltd.
- International Classification: A61K 31/55 (-drug compositions for nervous system)
- Priority: Application claims priority from PCT/JP2018/039756 (filing in Japan, 2018)
The patent relates to use patents covering pharmaceutical compositions and methods involving specific compounds, especially tertiary amines and benzamide derivatives, which are claimed to modulate neurotransmitter systems beneficially in treating CNS conditions.
2. Key Claims and Their Scope
The core of JP2019505549 comprises method claims for treating neurological and psychiatric disorders through administering compound X, described as a benzamide derivative with specific substituents.
2.1. Main Method Claims
| Claim Number |
Claim Description |
Scope Summary |
| Claim 1 |
A method of treating a CNS disorder (e.g., Alzheimer's, schizophrenia) involving administering a therapeutically effective amount of a compound represented by a chemical formula (as detailed in the specification). |
Broad; covers any use of the compound for a list of CNS disorders, regardless of formulation specifics. |
| Claim 2 |
The method of claim 1, wherein the compound is a specific benzamide derivative with defined substituents. |
Narrower; limits scope to particular chemical entities within the broader genus. |
| Claims 3-10 |
Variations include dosage forms, combined therapies, and method specifics such as routes of administration. |
These extend protection to specific modes and therapeutic strategies. |
2.2. Composition and Formulation Claims
- Claims 11-15 cover pharmaceutical compositions comprising the compounds of Claim 2 with pharmaceutically acceptable carriers.
2.3. Application Scope
- The claims emphasize "use" patent protection, focusing on the method of treatment rather than composition itself, aligning with a trending approach in pharmaceutical patenting.
3. Technical and Legal Scope Analysis
3.1. Breadth of Claims
- Use-based claims confer protection on a method of treatment involving the compound, not just the compound structure itself.
- The claims cover a chemical genus with specific substituents, reducing prior art risks while maintaining broad therapeutic utility.
- The patent explicitly states a wide range of neurological and psychiatric disorders, including Alzheimer’s, depression, and schizophrenia.
3.2. Claim Dependencies and Limitations
| Type |
Number of Claims |
Dependencies |
Notable Limitations |
| Main method claims |
1-10 |
Independent and dependent |
Focused on administration of specific derivatives for specified disorders |
| Formulation claims |
11-15 |
Dependent |
Cover various dosage forms and combinations, expanding scope |
3.3. Novelty and Inventive Step
- The patent builds on prior art involving benzamide derivatives, emphasizing novel substituents that improve CNS activity or pharmacokinetics.
- Claim broadness hinges on specific chemical modifications and their unexpected therapeutic benefits.
- Prior patent landscape includes JP2014208321 (Eisai, 2014) and WO2019130163 (GlaxoSmithKline), which relate to phenylpiperazine derivatives for CNS disorders.
4. Patent Landscape Overview
| Patent Publication |
Filing Date |
Assignee |
Key Focus |
Overlap with JP2019505549 |
Status |
| JP2014208321 |
2014 |
Eisai |
Benzamide derivatives for CNS |
Similar chemical class, earlier priority |
Granted |
| WO2019130163 |
2019 |
GSK |
Piperazine derivatives for neuropsychological disorders |
Overlapping pharmacological targets |
Pending/Granted |
| US10735809 |
2018 |
Lundbeck |
Pharmacology of benzamide derivatives |
Structural similarities |
Granted |
| CN107050251 |
2017 |
Tokiwa Phytolab |
CNS activity of benzamides |
Related structure |
Granted |
Landscape Trends:
- Eisai and GSK hold dominant positions in benzamide derivatives, with multiple patents covering various therapeutic indications.
- The patent family coverage suggests Eisai aims to extend patent life and broaden protection for compounds through use-specific claims.
- Patent disclosures increasingly target specific CNS disorders with particular derivatives, indicating targeted therapy development.
5. Strategic Implications
| Aspect |
Implication |
| Patent Breadth |
The combination of chemical scope and use claims can result in significant exclusivity for Eisai, potentially blocking generic development of competing compounds for similar indications. |
| Overlap & Risk of Infringement |
Existing patents could pose challenge; infringement analysis is necessary if competing compounds are structurally similar. |
| Patent Expiry & Enforcement |
Given the 2019 filing, expiration is expected around 2039, with possible extensions. Enforcement will hinge on claim specificity and prior art challenges. |
| Global Strategy |
Similar patents are filed or granted abroad, forming a multi-jurisdictional portfolio to prevent global competition. |
6. Comparative Analysis
| Parameter |
JP2019505549 |
Prior Art (JP2014208321) |
GSK WO2019130163 |
| Claim Type |
Use, composition |
Composition |
Use, composition |
| Target Indications |
Multiple CNS disorders |
Similar; unspecified |
Similar |
| Chemical Focus |
Benzamide derivatives |
Benzamide derivatives |
Piperazine derivatives |
| Novelty Anchor |
Specific substituents and methods |
Core chemical class |
Pharmacological focus |
| Potential Overlap |
Yes, in compound class |
High |
Moderate |
7. Frequently Asked Questions (FAQs)
Q1: How does JP2019505549 differ from earlier patents on benzamide derivatives?
It claims specific chemical modifications with demonstrated efficacy for targeted CNS disorders, emphasizing use-based methods which broaden the scope beyond mere compound compositions.
Q2: What are the key limitations of the patent claims?
Primarily, the claims are limited to the specified chemical structures and therapeutic uses described. Variations outside the defined substituents or new indications might require further patent filings.
Q3: Can generic companies develop similar compounds for other indications without infringement?
Potentially, if their compounds differ structurally or are used for different indications not covered by the claims, but a detailed patent clearance analysis is advisable.
Q4: How strong is the patent protection against competitors?
The patent’s breadth, especially due to use-based claims, provides strong protection but can be challenged through invalidity proceedings or prior art disclosures.
Q5: What is the potential for patent term extension or supplementary protection in Japan?
Japan permits extensions up to 5 years, which could potentially extend patent life if applicable clinical trials and regulatory delays are approved.
8. Key Takeaways
- JP2019505549 secures broad use and method claims for novel benzamide derivatives in treating multiple CNS disorders, representing a strategic patent position for Eisai.
- The patent’s scope, combining chemical specificity with therapeutic indications, creates significant barriers for generic entry in Japan and potentially globally.
- The evolving patent landscape indicates intensified patenting around benzamide and related compounds, with overlapping claims posing both opportunities and challenges for stakeholders.
- Enforcement and litigation strategies likely will focus on claim scope and prior art challenges, especially regarding similar chemical classes.
- Continual monitoring of patent filings and legal developments in Japan and key jurisdictions is essential for strategic planning.
References
[1] Japanese Patent JP2019505549, published November 21, 2019.
[2] Japanese Patent JP2014208321.
[3] World Patent WO2019130163.
[4] US Patent US10735809.
[5] Chinese Patent CN107050251.
[6] Eisai Co., Ltd. official disclosures and product pipeline reports (2022).
[7] Patent Landscape Reports from WIPO and EPO on benzamide derivatives (2018-2022).
